

# **Integrated Approach for LM PCI Using FFR and IVUS**



**Seung-Jung Park, MD, PhD**

Heart Institute, University of Ulsan College of Medicine  
Asan Medical Center, Seoul, Korea

# ***Q1,*** **Why FFR ?**


# Significant Stenosis Negative FFR

## 47/M Stable Angina




# Insignificant Sub Stenosis P<sub>Min</sub> ~~CFR~~

62/F Stable Angina



# Many Mismatch Intermediate LM Disease, Os/Shaft



# ***Predictors for FFR <0.80***

## **Multivariable Analysis, LM (n=112)**


Variables	OR	95%CI	p-value
<b>Model 1</b>			
MLA, mm <sup>2</sup>	0.37	0.25-0.56	<0.001
Plaque rupture	4.51	1.36-14.9	0.014
Age, year	0.95	0.90-1.00	0.033
BMI, kg/m <sup>2</sup>	1.19	1.00-1.40	0.05
<b>Model 2</b>			
MLA, mm <sup>2</sup>	0.34	0.21-0.54	<0.001
Age, year	0.94	0.90-0.99	0.022
LV mass, g	1.01	1.00-1.03	0.03

Model 1 included clinical, QCA, and IVUS variables

Model 2 included Model 1 plus LV mass assessed by **Echocardiography**

# How I Implement FFR in Real Practice ?

# For the Undetermined, Intermediate Ostial and Shaft LM Lesion,




FFR is Crucial



# For Intermediate **Bifurcation** LM Lesion,

If Transducer Placed Beyond Bifurcation  
in both LAD and LCX,




Single Unit of Disease

**Composite FFR still Works.**


# LM Bifurcation Disease

*Medina (1,0,0)*




55/M, Stable angina, TMT (+), Thallium scan (-)




# FFR in Both LAD and LCX,




# IVUS in Both LAD and LCX,



# Single Stent Cross-Over !




Promus Element 4.0x20



Additional high pressure  
Inflation with 4.0 mm  
non-compliant balloon



# After Stent Crossover, LCX Ostium Was Jailed !



What Would You Do ?


# Do You Want to Treat Jailed Side Branch ?

## *Consider FFR, First !*



## *Just Defer !*



# **Functionally Significant LCX Jailing After Stent Crossover (LCX ostial DS<50%)**







# Mechanism of LCX Jailing

Mainly,  
Carina Shift



Plaque  
Redistribution




# *Morphology* Cannot Predict LCX FFR

**FFR 0.91**

**FFR 0.81**

**FFR 0.85**






***Carina shift***




***Carina shift***



***Plaque shift***




# Left Main-TLR *at 2 Years*




## No. at Risk

FKB	95	79	74
No-FKB	318	293	265

# Death or MI *at 2 Years*



***Defer Is Safe and Good !***



**No. at Risk**

FKB	95	85	80
No-FKB	318	300	278


# **Q1, Why FFR ?**

---

1. Angiographic Assessment is *Not Always Enough !*  
Decision Making To Treat or Not To Treat for Intermediate LM Stenosis, *FFR is Crucial !*
2. Decision Making To Treat or Not To Treat for Side Branch Jailing after Main Stent Crossover, *FFR Should Be Considered First !* Routine Kissing Balloon Inflation is Not Always Good.

**Q2,**  
**Why IVUS too ?**

# IVUS Guidance Saved Lives !



Patients after risk

IVUS-guidance	145	140	98	37
Angiography-guidance	145	137	88	29

# Impact Of IVUS

① *Decision Making ;*  
*1 Stent or 2 Stents ?*




# Stent Strategy for Distal LM Bifurcation

<b>Stent Cross Over</b>	<b><i>Normal Ostial LCX (Medina 1.1.0., 1.0.0)</i></b> Normal or Diminutive LCX Small LCX with < 2.5 mm in diameter Focal disease in distal LCX
<b>Two Stent</b>	<b><i>Diseased LCX (Medina 1.1.1., 1.0.1)</i></b> Large LCX with $\geq 2.5$ mm in diameter Diseased left dominant coronary system Concomitant diffuse disease in distal LCX





Park SJ, Kim YH. Colombo A, Issam D. Moussa et al.  
Textbook of Bifurcation Stenting 2007

# Restenosis at 2 year

Pooled Analysis in 403 Patients with LM PCI Using SES



# ***Depending*** on Whether or LCX Disease,



# Impact Of IVUS

## ② *Stent Optimization ; After 2 DES Stents*

# 2 Stent Techniques

- T-stent, modified T-stent or TAP
- Mini-crush (or step crush)
- Culotte
- V-stent
- Y-stent (SKS-simultaneous kissing stents)

# 2 Stents Technique, *Effective IVUS Stent Area (Rule of 5,6,7,8)* Can Reduce Restenosis Rate




*Overall* Restenosis Rate < 5%,  
TLR < 2%

**6 mm<sup>2</sup>**



# Issue of ***LM IVUS MLA*** (Ischemic Threshold)

# LM, IVUS MLA < 6.0 mm<sup>2</sup> Matched with FFR < 0.75





# Non-LM, *IVUS MLA* Matched with FFR


	N	FFR	RLA	MLA mm <sup>2</sup>	AUC	Sens	Spec	PPV	NPV	Accu
Abizaid (1998, AJC)	112	CFR	8.3	<b>4.0</b>						
Nishioka (1999, JACC)	70	SPECT	10.6	<b>4.0</b>						
Briguori (2001, AJC)	53	0.75	7.8	<b>4.0</b>	–	92%	56%	38%	96%	64%
Waksman (2013, JACC)	350	0.80	8.6	<b>3.07</b>	0.65	64%	65%	–	–	65%
Kang (2012, AJC)	784	0.80	8.2	<b>2.4</b>	0.77	84%	63%	48%	90%	69%
Kang (2011, Circ int)	236	0.80	7.6	<b>2.4</b>	0.80	90%	60%	37%	96%	68%
Koo (2011, JACC int)	267	0.80	6.8	<b>2.75</b>	0.81	69%	65%	27%	81%	67%
Lee (2010, AJC)	94	0.75	5.9	<b>2.0</b>	0.80	82%	81%	–	–	81%
Gonzalo (2012, JACC)	47	0.80	7.1	<b>2.36</b>	0.63	67%	65%	67%	65%	66%
Stone (2012, VERDICT – FIRST)	554	0.80		<b>2.9</b>				47%	81%	66

# Background

## Geometric Abstraction By Murray's Law


**Old  
Data**

		Murray's	Finet's
LAD	LCX	LM	LM
4.0	4.0	6.35	7.35
4.0	3.9	6.27	7.26
4.0	3.8	6.19	7.17
4.0	3.7	6.11	7.08
4.0	3.6	6.04	6.98
4.0	3.5	5.96	6.89



**New  
Data**


		Murray's	Finet's
LAD	LCX	LM	LM
3.0	3.0	4.76	5.52
3.0	2.9	4.68	5.42
3.0	2.8	4.60	5.33
3.0	2.7	4.53	5.24
3.0	2.6	4.45	5.14
3.0	2.5	4.37	5.05



# New IVUS MLA

Matched with FFR <0.80

Ostial and Shaft LM Disease (N=112)



**Cut-off = 4.5 mm<sup>2</sup>**

Sensitivity	79%
Specificity	80%
PPV	83%
NPV	76%
Accuracy	80%

# Q2, Why IVUS Too ?

---

1. IVUS Guidance Saves Lives.
2. Assessment of LM Ostium, Reference Vessel Diameter, Pattern of Remodeling, and Vulnerability of Plaque.
3. Treatment Strategy Would be Simplified as Single Stent Cross-Over Depending on the Disease Status of LCX Ostium by Separate IVUS Run.
4. IVUS Guided Stent Optimization and Effective Stent CSA (Rule of 5,6,7,8 mm<sup>2</sup>) Can Make a Good Clinical Outcomes.
5. Smaller IVUS MLA 4.5 mm<sup>2</sup> Can Predict Functional Significance of LM Stenosis.

# Integrated Use of FFR and IVUS

*Less DES,  
Less Surgery,  
Simplified Procedure, and  
Improved Clinical Outcomes !*